Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Open Access
- 1 January 2009
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 11 (Suppl 1), S1-12
- https://doi.org/10.1186/ar2666
Abstract
Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, which act by inhibiting tumour necrosis factor (TNF), have become available. TNF inhibitors have proved to be very effective in patients not responding to conventional disease-modifying antirheumatic drugs. However, about 20% to 40% of patients treated with a TNF inhibitor fail to achieve a 20% improvement in American College of Rheumatology criteria, and more lose response over time (secondary failure or acquired therapeutic resistance) or experience adverse events following treatment with a TNF inhibitor. In this group of patients, therapeutic options were limited until recently and an established treatment approach was to switch from one TNF inhibitor to another. In recent years, therapeutic options in these patients have increased with the introduction of biologic agents with novel mechanisms of action, such as rituximab and abatacept. This review outlines the current evidence in support of the available treatment strategies in patients with an inadequate response or intolerance to an initial TNF inhibitor.This publication has 48 references indexed in Scilit:
- Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals Of The Rheumatic Diseases, 2009
- Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapyArthritis Care & Research, 2008
- Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drugRheumatology, 2008
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Annals Of The Rheumatic Diseases, 2007
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnnals Of The Rheumatic Diseases, 2007
- Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practiceRheumatology, 2007
- Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial respondersRheumatology, 2007
- Switching between anti-tumour necrosis factors: trying to get a handle on a complex issueAnnals Of The Rheumatic Diseases, 2007
- Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyAnnals Of The Rheumatic Diseases, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006